The diagnostics industry has been a tarpit for start-ups. Entrepreneurs rarely overcome the field's serious and often unseen challenges, but a handful are thriving thanks to their realistic assessments of just how complex the industry is and their ability to adapt when products hit brick walls. Accessible market niches are a key to success, so is exploiting drug firms--as customers, marketing channels, or as sources of differentiating technology.
By Wendy Diller and Roger Longman
Diagnostics is a tricky field: on one hand, compared to pharmaceuticals, it is often viewed as a quicker, less expensive...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
The Development Bank of Wales and London-based Parkwalk Advisors led an investment round of £5m, almost doubling Ceryx Medical's total investment to date.
SS Innovations reported its first SSi Mantra 3 robotic cardiac surgery in South America as it prepares to file for US FDA de novo clearance and a CE mark. The firm aims to challenge Intuitive Surgical with a lower-cost, flexible system targeting US and European markets.
Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.
